Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results
dc.contributor.author | Tiseo, M. | |
dc.contributor.author | Popat, S. | |
dc.contributor.author | Kim, H. R. | |
dc.contributor.author | Ahn, M. J. | |
dc.contributor.author | Yang, J. C. | |
dc.contributor.author | Han, J. Y. | |
dc.contributor.author | Hochmair, M. J. | |
dc.contributor.author | Lee, K. H. | |
dc.contributor.author | Delmonte, A. | |
dc.contributor.author | Campelo, M. R. G. | |
dc.contributor.author | Kim, D. W. | |
dc.contributor.author | Griesinger, F. | |
dc.contributor.author | Felip, E. | |
dc.contributor.author | Califano, Raffaele | |
dc.contributor.author | Spira, A. I. | |
dc.contributor.author | Gettinger, S. N. | |
dc.contributor.author | Lin, H. M. | |
dc.contributor.author | Liu, Y. | |
dc.contributor.author | Vranceanu, F. | |
dc.contributor.author | Camidge, R. | |
dc.date.accessioned | 2022-04-28T13:57:37Z | |
dc.date.available | 2022-04-28T13:57:37Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Tiseo M, Popat S, Kim HR, Ahn M-J, Yang JC, Han J-Y, et al. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S44–5. | en |
dc.identifier.doi | 10.1016/j.annonc.2022.02.038 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625141 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.annonc.2022.02.038 | en |
dc.title | Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results | en |
dc.type | Meetings and Proceedings | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2022-06-28T09:38:07Z |